POS1169 IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION
Authors: H. Bower, T. Frisell, D. DI Giuseppe, B. Delcoigne, G. M. Alenius, E. Baecklund, K. Chatzidionysiou, N. Feltelius, H. Forsblad-D’elia, A. Kastbom, L. Klareskog, E. Lindqvist, U. Lindström, C. Turesson, C. Sjowall, J. Askling
Journal: Annals of the Rheumatic Diseases (2021)

Background: Studies from COVID-19 case-repositories among patients with rheumatic diseases have assessed associations (relative risks) between characteristics of the disease and adverse COVID-19 outcomes. Such designs are susceptible to bias from selection of cases reported. Few studies have assessed absolute and relative risks for COVID-19 outcomes in population-based cohorts of patients with inflammatory joint diseases, nor compared these risks to those in the general population. Objectives: To estimate all-cause mortality, absolute and relative risks for severe COVID-19 in patients with chronic inflammatory joint diseases, compared over time and to the general population. Methods: We updated a multi-register nationwide linkage (“ARTIS”) on adults with RA, PsA, AS, SpA or JIA and population referents (matched on sex, age, and region), with data on hospitalizations, admission to intensive care (ICU), and deaths due to COVID-19. We calculated all-cause mortality March-September 2015-2020, and absolute and relative risks for COVID-19 outcomes March-September 2020. Patients were compared to population referents using hazard ratios (HR) from Cox models adjusted for comorbidities and socio-economy. Results: We identified 110567 individuals with inflammatory joint disease (53455 with RA) in Sweden on March 1 st 2020, and 484277 matched general population subjects. In all cohorts, the absolute risk of death from any cause in 2020 was higher than 2015-2019 (Figure 1), with a peak in mid-April, but the relative risks of death (vs. the general population) 2020 remained similar to HRs for 2015-2019 (HR for 2020 in Table 1). Among all individuals with inflammatory joint disease in 2020, the risk for hospitalization, admission to ICU, and death due to COVID-19 was 0.5%, 0.04% and 0.1%, respectively (Table 1). HRs (vs. the general population) were elevated for almost all outcomes. HRs for COVID-19 related outcomes (Table 1) were higher than for non-COVID-19 outcomes; adjustment for co-morbidities and socio-economy explained much of these increases, somewhat less so for the former. Figure 1. All-cause mortality in Swedish individuals with inflammatory joint disease and general population, March-September 2020 and the average 2015-2019 Table 1. Absolute and relative risks for COVID-19 outcomes in Swedish individuals with inflammatory joint disease compared to general population comparators March-September 2020 Outcome Events (risk, % ) Events (risk, %), general population HR1* HR2** All Hospitalization, all causes 8971 (8.1%) 24273 (5.0%) 1.65 (1.61, 1.69) 1.18 (1.15, 1.21) Hospitalization, COVID-19 581 (0.5%) 1443 (0.3%) 1.77 (1.61, 1.95) 1.32 (1.19, 1.46) ICU, COVID-19 45 (0.04%) 162 (0.03%) 1.22 (0.88, 1.70) 1.17 (0.82, 1.66) Death, all causes 1310 (1.2%) 3036 (0.6%) 1.90 (1.78, 2.02) 1.13 (1.05, 1.21) Death, COVID-19 161 (0.1%) 338 (0.07%) 2.09 (1.73, 2.52) 1.18 (0.97, 1.44) RA Hospitalization, all causes 5275 (9.9%) 13072 (5.9%) 1.71 (1.66, 1.77) 1.21 (1.17, 1.25) Hospitalization, COVID-19 379 (0.7%) 784 (0.4%) 2.02 (1.78, 2.28) 1.40 (1.23, 1.60) ICU, COVID-19 31 (0.06%) 79 (0.04%) 1.63 (1.08, 2.48) 1.53 (0.98, 2.40) Death, all causes 968 (1.8%) 2026 (0.9%) 1.99 (1.85, 2.15) 1.18 (1.09, 1.28) Death, COVID-19 134 (0.3%) 245 (0.11%) 2.28 (1.85, 2.81) 1.27 (1.02, 1.59) PsA AS SpA JIA Hospitalization, all causes 3696 (6.5%) 11201 (4.3%) 1.54 (1.48, 1.59) 1.16 (1.11, 1.20) Hospitalization, COVID-19 202 (0.4%) 659 (0.3%) 1.41 (1.20, 1.65) 1.20 (1.02, 1.41) ICU, COVID-19 14 (0.02%) 83 (0.03%) 0.78 (0.44, 1.37) 0.76 (0.43, 1.37) Death, all causes 342 (0.6%) 1010 (0.4%) 1.56 (1.38, 1.76) 0.98 (0.86, 1.12) Death, COVID-19 27 (0.05%) 93 (0.04%) 1.34 (0.87, 2.05) 0.83 (0.54, 1.28) *HR1 unadjusted, matched (age, sex, and region) **HR2, as HR1 but adjusted for comorbidities and socio-economy Conclusion: Risks of severe COVID-19 were increased among patients with inflammatory joint diseases, but similar increases were seen for non-COVID-19 morbidity. Co-morbidities and socio-economy explain much of this increase. Disclosure of Interests: Hannah Bower: None declared, Thomas Frisell: None declared, Daniela Di Giuseppe: None declared, Bénédicte Delcoigne: None declared, Gerd-Marie Alenius: None declared, Eva Baecklund: None declared, Katerina Chatzidionysiou Speakers bureau: Eli Lilly, AbbVie and Pfizer, Consultant of: Eli Lilly, AbbVie and Pfizer, Nils Feltelius Employee of: Nils Feltelius is employed by the Medical Products Agency (MPA), which is a governmental body. The views in this abstract may not represent the views of the MPA, Helena Forsblad-d’Elia: None declared, Alf Kastbom Employee of: Former employee of Sanofi, Lars Klareskog: None declared, Elisabet Lindqvist: None declared, Ulf Lindström: None declared, Carl Turesson Speakers bureau: Roche, AbbVie and Pfizer, Consultant of: Roche, Grant/research support from: Research grant from Bristol-Myers Squibb, Christopher Sjowall: None declared, Johan Askling Grant/research support from: PI for agreements between Karolinska Institutet and Abbvie, BMS, Eli Lilly, Pfizer, Roche, Samsung Bioepis, and Sanofi for safety monitoring of anti-rheumatic therapies (ARTIS).